

# Real-Time Reverse Transcription-PCR Expression Profiling of the Complete Human ATP-Binding Cassette Transporter Superfamily in Various Tissues

THOMAS LANGMANN,<sup>1\*</sup> RICHARD MAUERER,<sup>1\*</sup> ALEXANDRA ZAHN,<sup>2\*</sup> CHRISTOPH MOEHLE,<sup>1\*</sup>  
MARIO PROBST,<sup>1</sup> WOLFGANG STREMMEL,<sup>2</sup> and GERD SCHMITZ<sup>1†</sup>

**Background:** ATP-binding cassette (ABC) transporters are involved in many physiologic processes, such as lipid transport, sterol homeostasis, immune mechanisms, and drug transport, and cause various human inherited diseases. Thus, the analysis of ABC transporter mRNA expression profiles for basic research, especially in the field of lipid metabolism, for clinical diagnosis, and for monitoring of drug effects is of great interest.

**Methods:** We have developed a rapid, accurate, and highly sensitive real-time reverse transcription-PCR (RT-PCR) method for detection and quantification of all 47 currently known members of the ABC transporter superfamily. Our expression analysis is based on relative quantification using a calibration curve method. With our assay, expression monitoring of a large number of RNA samples in a 384-well format with only 50 ng of total RNA is possible.

**Results:** In contrast to previous expression analyses of single ABC genes, our method allows the rapid and complete analysis of all ABC transporters in given RNA samples. We used our newly established expression panel to study the gene expression of all human ABC transporters in 20 different human tissues. As a result, we identified tissues with high transcriptional activity for ABC transporters. These organs are mainly involved

in secretory function (adrenal gland), metabolic function (liver), barrier function (lung, trachea, small intestine), and tropic function (placenta, uterus).

**Conclusions:** Our RT-PCR assay allows rapid, high-throughput transcriptional profiling of the complete ABC transporter superfamily and thus provides a new enabling tool for research, clinical diagnosis of disease, and drug testing and development.

© 2003 American Association for Clinical Chemistry

ATP-binding cassette (ABC)<sup>3</sup> transporters are multispan membrane proteins that promote either the active uptake or efflux of specific substrates across various biological membrane systems (e.g., ABCB1) (1, 2) or function as regulatory molecules, such as ABCC7 (CFTR) (3, 4), ABCC8 (SUR1) (5), and ABCA1 (6). On the basis of sequence motifs in the signature region of the ABC, a new nomenclature that divides the ABC proteins into seven subfamilies, ABCA to ABCG, has been proposed (7). Several ABC proteins in the human system are responsible for drug exclusion in compound-treated tumor cells, providing cellular mechanisms for the development of multidrug resistance (8). Recently, several human ABC transporters have been implicated in bile acid, phospholipid, and sterol transport (9–12), in which the expression of these transporters is itself controlled by lipids. Therefore, and because ABC genes are prone to be involved in human genetic disorders, ABC transporters are promising target molecules for the treatment of lipid disorders such as cardiovascular disease (13). These important findings underscore the need for a sensitive, rapid, and accurate

<sup>1</sup> Institute for Clinical Chemistry, University of Regensburg, 93042 Regensburg, Germany.

<sup>2</sup> Institute for Internal Medicine IV, University of Heidelberg, 69115 Heidelberg, Germany.

\*These authors contributed equally to the work.

†Address correspondence to this author at: Universitätsklinikum Regensburg Institut für Klinische Chemie und Laboratoriumsmedizin, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany. Fax 49-941-944-6202; e-mail gerd.schmitz@klinik.uni-regensburg.de.

Received September 6, 2002; accepted October 31, 2002.

<sup>3</sup> Nonstandard abbreviations: ABC, ATP-binding cassette; RT-PCR, reverse transcription-PCR; FAM, 6-carboxyfluorescein; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; and Ct, threshold cycle.

method for quantification of ABC transporter expression, and a systematic investigation of these molecules in human tissues is thus warranted.

Traditionally, tissue localization and changes in gene expression after stimulation of cells have been monitored by Northern blot analysis, dot-blot analysis, competitive PCR, RNase protection assays, or in situ hybridization. Although these methods are widely accepted and reliable, they require large amounts of RNA and starting material and are usually not amenable to rapid analysis of multiple genes and large sample numbers. In particular, complete analysis of the ABC transporter superfamily in given samples would not be possible.

TaqMan<sup>®</sup> reverse transcription-PCR (RT-PCR) is a relatively new method that allows real-time measurement of accumulating PCR product based on the 5' nuclease assay, which uses the 5'-3' exonuclease activity of *Taq* polymerase to cleave a dual-labeled probe, which in turn hybridizes to a target sequence during amplification (14). The TaqMan probe contains a fluorescent reporter dye at the 5' end and a quencher dye at the 3' end. As long as the probe is intact, the proximity of the reporter to the quencher suppresses the reporter fluorescence by a Förster-type energy transfer. Disintegration of the probe during TaqMan PCR releases reporter fluorescence, and the intensity of the fluorescence signal measured during the exponential phase of the PCR reaction is proportional to the amount of input target DNA. The resulting fluorescence signal is monitored with an ABI Prism 7900 HT Sequence Detection System (Applied Biosystems), which allows sample processing in a 384-well format and provides the basis for further automation, enabling high-throughput RT-PCR analysis.

Because there are few reports describing the use of TaqMan technology for quantification of ABC transporters, the aim of this study was to establish step by step a complete panel of TaqMan RT-PCR assays for all 47 currently known human ABC molecules. All required information to adapt the method for the individual purposes of researchers and clinical laboratories, including primers and probe sequences as well as complete PCR conditions, are provided. Because only scattered information is available regarding the expression of ABC transporters in human tissue samples, we validated our relative expression method in 20 different human tissues. In the present study, we demonstrate that human tissues vary greatly in ABC transporter expression, with heart and skeletal muscle showing the lowest expression of ABC molecules. In contrast, tissues with high secretion (adrenal gland), metabolic activity (liver), and barrier function (lung, trachea) and organs of the reproductive system (prostate, placenta, uterus) display broad, high expression of ABC transporters. Although most of the ABC transporters are ubiquitously expressed, some members display a very restricted expression pattern, e.g., ABCA3 in the lung, ABCB4 and ABCB11 in the liver and the testis, and ABCG5 and ABCG8 in the liver and the gut.

## Materials and Methods

### TISSUE ACQUISITION AND RNA EXTRACTION

HepG2 cells were obtained from the American Type Culture Collection. The cells were cultured in DMEM (BioWhittaker) supplemented with 100 mL/L heat-inactivated fetal calf serum (Sigma) and incubated in a 5% CO<sub>2</sub> atmosphere at 37 °C. Harvesting of cells and RNA extraction were carried out according to the manufacturer's instructions using the RNeasy Midi Kit (Qiagen).

The purity and integrity of the RNA were assessed on the Agilent 2100 bioanalyzer with the RNA 6000 Nano LabChip reagent set (Agilent Technologies). The RNA was quantified spectrophotometrically and then stored at -80 °C.

Human total RNA samples were obtained from Clontech (BD Biosciences Clontech). The RNA panel for the 20 human tissues contained different numbers of individuals between 14 and 70 years of age. The lowest number of individuals was 2 male/female Caucasians for skeletal muscle, and the highest number was 83 male/female Caucasians for bone marrow.

### cDNA SYNTHESIS

First-strand cDNA synthesis was performed with the Reverse Transcription System from Promega. To a master mixture (prepared in house) containing 5 mM MgCl<sub>2</sub>, 1× reverse transcription buffer, 1 mM deoxynucleotide triphosphate mixture, 1 unit/ $\mu$ L recombinant RNasin<sup>®</sup> ribonuclease inhibitor, 0.75 U/ $\mu$ L AMV reverse transcriptase, and 1  $\mu$ g of random hexamer primers, we added 2  $\mu$ g of total RNA and sterile H<sub>2</sub>O to a final volume of 40  $\mu$ L.

The reaction mixture was incubated at 42 °C for 60 min, followed by heat inactivation of the enzyme at 95 °C for 5 min. After cooling on ice for 5 min, the cDNA was stored at -20 °C.

### PRIMERS AND TaqMan PROBE DESIGN

mRNA sequences for all human ABC transporters were derived from GenBank (for accession numbers, see Table 1), and primers and TaqMan probes were designed with PrimerExpress Software, Ver. 2.0 (Applied Biosystems). Because of the strict primer and probe design criteria for optimal assays, we did not purposefully target the primers and probes to exon/intron boundaries. All primers and 6-carboxyfluorescein (FAM)-labeled probes were obtained from MWG-Biotech. For the normalization of our results, we used a VIC<sup>™</sup>-labeled glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) TaqMan PDAR endogenous control reagent set (Applied Biosystems). Each of the probes was quenched by 6-carboxytetramethylrhodamine (TAMRA) at its 3' end.

### PRIMER AND PROBE QUALITY CONTROL

In preliminary experiments, we determined optimum primer and probe concentrations for 12 different ABC transporter genes. We combined three concentrations (50,

Table 1. Gene-specific primers and probes for TaqMan analysis.

Gene	Alternative name	Forward primer, 5'-3'	Probe, 5'-3'	Reverse primer, 5'-3'	GenBank accession no.	Position, bp
ABCA1	ABCI	TGTCAGTCCAGTAATGGTTCTGT	TACACCTGGAGAGAGCTTTCAACGAGACTAACCC	CGAGATATGGTCCGGATTGC	NM_005502	1359-1439
ABCA2	ABCI	AAGCTGTGGAGGATGATGTG	TGGCCAGTGGAGCCGACGG	GGTCAACGGCCAGGATACG	NM_001606	6224-6365
ABCA3	ABCI	CAAAACCCTGGATACGGTGT	TGCTGCCAACCACTGTCTGGG	CTCCGGCTGCTCGTAGTCT	NM_001089	4285-4375
ABCA4	ABCI	AAAGTTGCAAACTGGAGTAAAGAG	CTGGCCGTACTGCTACGCCGA	TTGTTCCCCCACTGACGT	NM_00350	6225-6308
ABCA5	ABCI	GGGTCTATTGACCACTCACTATA	CAGAGGCTGTGTGATCGAGTAGC	TTAAGTCCCCAGACACCATGAT	NM_018672	5462-5544
ABCA6	ABCI	CCATGAGAAATGTCCAGTTTCCCT	TCCTCAGAATCTGGAGGAGTAGATAAA	TGCTGGTTAAATAGATTTGGTGA	NM_080284	324-438
ABCA7	ABCI	TTTCTGGGACATGTAACTACTTG	CCCTCCAGCAGAGGGCATATGTG	TGTGATCGACAGCCATACAG	XM_055173	4337-4480
ABCA8	ABCI	TGCTAGTCCCTTGGCTTCA	AAATGGCCAGCTTTACACTGGACTATGATT	GAGCCGTCGGATGATGA	NM_007168	1226-1322
ABCA9	ABCI	CATTACAGCTGACAGAACACATTT	TGGATTATGAGTATGGTACCGAAGTAA	TCACCAATGCTGCTCAATTC	NM_080283	3152-3283
ABCA10	ABCI	ATCAAACTGGCTTCTCCCTT	ATCCGCATGACAGCAGCAGCA	CAGAGCCCTGAATCCATAACTG	NM_080282	3703-3794
ABCA11	ABCI	CTCCATTAGCACCAGAAAGTCT	CTCCACTGTACTCCAGGCCACTCG	GAGAGCCACCCATGCCATT	NM_015657	4066-4141
ABCB1	MDR1	GTCCAGAGCCCATCCT	TTGACTGACGATTTGCTGAGAACATTTGC	CCCGCTGTGTTCTCCATA	NM_000927	3769-3836
ABCB2	TAP1	GGGTGACGGGATCTATAACAACA	CATGGGCCACGTGCACAGCC	CCAAACAC CTCCTCCCTGCAA	XM_042533	942-1007
ABCB3	TAP2	ACAGCCAGGTGTTTCAAGTTG	CCCTGTGCTTCTCCGGTCT	GCCATAAGCAATGTTGTTCT	XM_165824	1724-1798
ABCB4	MDR3	TTTTACTTTTCTTCCAGGGTTTC	CGTTTTGGAAAGCTGGCGAGATCC	TAAAGCCATTGACGCGAGTCT	XM_167466	2869-2949
ABCB5	ABCI	GCTCTGGCCCTCAAACC	CACCCCTGACCTCCTGCTGCCTATGA	TGGCCTTGGAGTATGCGAGTA	U66692	218-285
ABCB6	MTABC3	TGAAAGAGGAGACAGAAGTGAAGGA	CTGGAGCAGGGCCCTTCCG	AACTCAATACGGCCCTTCTGAA	XM_050891	1980-2052
ABCB7	ABCI	GATCCGGCTTATGCTCTGTTAG	AGGTCGCCAGTGGAGGCCACA	CCAAAGCCCGGAGTTG	XM_032877	88-155
ABCB8	MABC1	GAAGCGAATGCTCACGAGTTC	TCACCAGCTTCCCGAGGGCT	TCACCGACGACCGTGTG	XM_032165	1775-1836
ABCB9	ABCI	CGCCACCTCCAACCA	AGGATGGGCTGTGGAAGGCC	CGAGGATCCACACTCATGA	XM_038794	266-344
ABCB10	MTABC2	GCTCCGTAGGCATCAGTATGAT	TTTTTTGCTCACCTAATCTGGCCACCTTTG	GGAGGATCCAGCGTCAAAA	XM_001871	941-1014
ABCB11	BSEP	AGGAGCTACCAGGATGTTAAGG	CTTCCATCCGGCAACGCTCA	TCGTGACACAGTAAAGAGC	XM_002644	2178-2253
ABCC1 <sup>a</sup>	MRP1	GAAGCCATCGGACTCTTCA	CTCCTTCTCAGCATCTCTTCTTCTGATG	CAGCGGGACACATGTT	L05628	3097-3166
ABCC2 <sup>a</sup>	MRP2	TGCAGCTCCATAACCATGAG	AGAGAAACAGCTTCTGCGAACACTAGCC	GATCCCTGCCATTTGGACCTA	U63970	2728-2807
ABCC3 <sup>a</sup>	MRP3	CACACGGATCTGACAGACAATGA	CCAGTCCCTATGTTGTCGAGAACAGTCT	ACAGGGCACTAGCTGTCTCA	AB_010887	2670-2745
ABCC4 <sup>a</sup>	MRP4	AAGTGAACACCTCCAGTCCAG	CAACCGAAGACTGAGAAGGTACGATCCCT	GGCTCCAGACACCATCT	AF_071202	2026-2144
ABCC5 <sup>a</sup>	MRP5	TGAAAGCCATCCGAGGAGTTG	CTGCGAGCTGCCCTTGACAAAG	CGGAAAAGCTGCTGATGCA	AF_146074	2979-3054
ABCC6 <sup>a</sup>	MRP6	AGACCGGTTGACGTGGACAT	CCAGACAACTCCGGTCCCTGCTGAT	GCTGACCTCCAGGAGTCCAA	AF_168791	3156-3231
ABCC7	CFTR	GGCACGAGGAGGCGAGTCT	TGATGACACACTCAGTTAACCAAGGTCA	TGCTGGATGCTGTTGCTTT	XM_004980	2418-2508
ABCC8	SUR1	CACCAATCAGCTCATGTGGTTT	CCAGTACAGATCATTGGGGTGTGAT	GGCACTGACTCCGAGTATGATAGA	XM_036347	1398-1506
ABCC9	SUR2	CTACTCTGTGTTCTGTTGCT	TCCTGCCCTTGGTGTGC	CAACCCGAAAGTATTTGGATAAA	XM_012243	3393-3467
ABCC10	MRP7	GCGGTTAAGCTTGTGACAGA	CTGCTGAGTGGCAATCGGGTC	CCCACCCGACAACTTGA	XM_052745	1585-1646
ABCC11	MRP8	AGGTTCTACCACACTACATCCA	CAGCTGGAGTTACATGTTCTCTTGCATAAT	CGATCAGCACCAAGAAAG	NM_033151	2721-2799
ABCC12	MRP9	TTCATCCAAAGCCCTGCAT	CATACATCAGCTGAGCCGACTGCT	CCGTTCCGACACACACTTG	NM_033226	3505-3575
ABCD1	ALD	CCTCTTCTACAGCCTAATTTATGGA	TCCTATTGTAGCCATCTCCG	TGGCACGGTAGTCCACTGG	NM_000033	3244-3316
ABCD2	ALDR	GCTACCTCTGTCAACAGTGC	AGGTAAGTGAATGAAATGGCT	CGTGGTCTACTAGCCGAGTCTG	NM_005164	1026-1104
ABCD3	PMP70	ACCCCTCAGTCTGCAGTATG	TGTTAAAGTATATGTCAGTCTGCT	TGATACATGGTAAACCCCTCTTGT	XM_040463	2497-2574
ABCD4	PMP69	GGCCAGGTTAGATCTGCAA	CCAGCGGTTCTGCGAGTACTGA	TGATACCAAGGAAACAAAAC	NM_005050	89-162
ABCE1	OABP	GATCGGCTATCGTTTTGA	TGTTCCATCTAAGAACACAGTTGCAAC	ATGCCGCAAAAGGGTTT	XM_017177	578-654
ABCF1	ABCF0	GAAGTTCAGCATCTCCGCTCAT	AGGAGCTGTTGTCATGACAGCCCTGATC	GGCGCCGGCTACAA	NM_001090	901-971
ABCF2	ABCF2	TGGAGCAGGGAAGTCAACTCTT	TGAAGCTGCTAACTGGAGAGCTACTACC	TTTTGGATCATGCCATCTG	NM_005692	1342-1414
ABCF3	ABCF3	CCGAGGTTGTGGTATGC	AAGGAGGCGGCTCACCCG	GTACTGCTAAATCCTCTTCCA	U66685	769-832
ABCG1	White	CCGACCGACACACAGAGA	TCTGATCCAAACCCCTAGAACCCGCT	GCACGACACACCAAAACC	NM_032950	2703-2772
ABCG2 <sup>a</sup>	MXR	CAGTCTGTTGGTCAATCTCACA	CCATTCATCTGGCTGTCATGGCTT	TCCATATGTTGAAATGCTGAAG	AF_098951	1893-1969
ABCG4	White2	GAGCCAGGTCAGTGCATCT	CAAAAGGCTGGTCCACCAACCTGATC	GCAAGCCGAGTCCCTTTAGA	XM_012099	823-893
ABCG5	White3	TCCTTGGCCCCCCTTCA	TTGGTGAATTTTCAACTCTTGTCT	CTATATTTGATTTTGGACGATACCA	NM_022436	1655-1728
ABCG8	White4	TC GTACCCTCTCTACGCCATCT	CGTCAATGGCCCTCAGCGGT	GGACACGTTAGTACAGGACCATGAA	XM_055525	1999-2073

<sup>a</sup> Primers and probes were adapted from Taipalensuu et al. (37).

300, 900 nM) of both forward and reverse primers with a constant probe concentration. The combination showing the highest fluorescence was tested thereafter at five different probe concentrations (50, 100, 150, 200, 250 nM).

Because almost all of the tested ABC transporter assays provided the best results at both the highest primer (900 nM) and probe (250 nM) concentrations, we chose these concentrations for further experiments.

#### GENERATION OF CALIBRATION CURVES

To quantify the results obtained by real-time PCR, we used a calibration curve. For this purpose, we prepared a stock solution of cDNA from HepG2 total RNA from which we prepared serial dilutions in four steps. A calibration curve with 50, 25, 12.5, 6.25 ng of HepG2 total RNA was created for all ABC transporters except ABCA6, ABCA8, ABCA9, ABCA10, ABCB11, ABCC1, and ABCC7. These molecules are not expressed in HepG2 cells; therefore, the calibration curves were created from testis cDNA in a similar manner. When necessary, e.g., in the case of very low expression, we prepared additional dilutions to construct calibration curves covering the complete range of expression.

#### TaqMan PCR

TaqMan PCR assays were performed on an ABI Prism 7900 HT Sequence Detection System (Perkin-Elmer Applied Biosystems). For quantification of each ABC transporter gene, we prepared a master mixture containing 10  $\mu$ L of 2 $\times$  TaqMan Universal PCR Master Mix, 1  $\mu$ L of gene-specific forward and 1  $\mu$ L of reverse primer (each at 18  $\mu$ M), 1  $\mu$ L of the gene-specific probe (5  $\mu$ M), and 2  $\mu$ L of sterile water and aliquoted it into the wells of a 384-well optical plate. A master mixture for the endogenous control *GAPDH*, containing 10  $\mu$ L of 2 $\times$  TaqMan Universal PCR Master Mix, 1  $\mu$ L of predeveloped TaqMan assay reagents (PDAR) from the endogenous control reagent set, and 4  $\mu$ L sterile water, was treated similarly. Finally, triplicates of cDNA templates equivalent to 50 ng of RNA were added to a final volume of 20  $\mu$ L.

The thermal cycling conditions were 2 min at 50  $^{\circ}$ C and 10 min at 95  $^{\circ}$ C, followed by 45 cycles of 15 s at 95  $^{\circ}$ C and 1 min at 60  $^{\circ}$ C.

#### DATA ANALYSIS

The Sequence Detector Software SDS 2.0 (Applied Biosystems) was used for data analysis. The first step was to generate an amplification plot for every sample, which showed  $\Delta$ Rn on the *y* axis (where Rn is the fluorescence emission intensity of the reporter dye normalized to a passive reference, and  $\Delta$ Rn is the Rn of an unreacted sample minus the Rn value of the reaction) against the cycle number, displayed on the *x* axis. From each amplification plot, a threshold cycle (Ct) value was calculated, which is defined as the cycle at which a statistically significant increase in  $\Delta$ Rn is first detected and is displayed in the graph as the intercept point of the amplification curve with the threshold. The threshold is automat-

ically calculated by SDS as the 10-fold SD of Rn in the first 15 cycles. The obtained Ct values were then exported to a Microsoft Excel spreadsheet for further analysis.

The next step was to construct calibration curve plots, using Microsoft Excel as recommended in User Bulletin 2 for the ABI Prism 7700 Sequence Detection System (Applied Biosystems), showing Ct values on the *y* axis and the logarithm of the input amount of cDNA (equivalent to the amount of total RNA) on the *x* axis.

All human ABC transporters were subsequently measured in the different human tissues, and the obtained Ct values were used to calculate the initial input amount. Thereafter the results were normalized to the endogenous control, *GAPDH*.

In the last step, we compared the expression of each individual ABC transporter in the complete tissue panel. Therefore, for each ABC transporter, the normalized amount of expression in the tissue that showed the lowest expression was used as a calibrator (set to 1), and the remaining tissue samples were displayed as fold changes.

## Results

#### SETUP AND OPTIMIZATION OF TaqMan RT-PCR CONDITIONS FOR SELECTED ABC TRANSPORTERS

The first step in developing a real-time quantitative RT-PCR based on the TaqMan chemistry for analysis of human ABC transporters involved the design of specific PCR primers and fluorogenic probes. After collection of the correct consensus sequences for all human ABC transporter mRNAs by GenBank screening, we used the Primer Express Software to design optimum and specific primer and probe combinations (Table 1). Except for ABCA13, primers and the corresponding TaqMan probes could be created for all 47 currently known human ABC transporters. Thereafter, experimental primer and probe concentrations were tested for 12 selected genes of the ABC transporter superfamily (Fig. 1). A primer matrix containing various concentrations of forward and reverse primers (50, 300, and 900 nM) was used for real-time PCR of ABC transporter transcripts in 50 ng of HepG2 cDNA (Fig. 1A). Similarly, several probe concentrations (50, 100, 150, 200, and 250 nM) with fixed amounts of cDNA (50 ng) and primers (900 nM each of the forward and reverse primers) were tested (Fig. 1B). As a result, the TaqMan PCR conditions that provided the highest possible  $\Delta$ Rn and lowest possible Ct values were achieved with highest primer (900 nM) and probe concentrations (250 nM). Therefore, these PCR conditions were used for all further assays with the remaining ABC transporters.

To construct calibration curves for relative quantification, we performed real-time amplification of several cDNA dilutions with ABC transporter genes and a reference gene. Shown in Fig. 2A are representative examples for *ABCB1* and *GAPDH*. The Ct values plotted vs the log concentrations of these calibration samples showed an inverse linear correlation; the correlation coefficient for each calibrator thus should be close to 1. The correlation coefficients for the




Fig. 1. Results of preliminary TaqMan assays to determine optimum primer and TaqMan probe concentrations.

Normalized fluorescence values ( $\Delta R_n$ ) on the *y* axis were plotted against PCR cycles on the *x* axis in a linear scale. (A), various combinations of both forward and reverse primers at three different concentrations (50, 300, 900 nM) and a fixed probe concentration (250 nM) were tested with 50 ng of HepG2 cDNA for 12 ABC transporters. Panel A shows a representative amplification plot for *ABCB1* (*MDR1*). (B), the primer pair achieving the highest  $\Delta R_n$  and the lowest Ct value (900 nM each of forward and reverse primer) was chosen to evaluate the optimum probe concentration. Probe concentrations in a range between 50 and 250 nM in steps of 50 nM were tested. For all tested transporters, 250 nM was the optimum concentration, i.e., that provided the lowest Ct values.

calibration curves of *ABCG2* and *GAPDH* (Fig. 2B) were 0.9891 and 0.9976, respectively. A similar relationship was observed in our experiments with all primers and probe sets used in mRNA expression analysis; the correlation coefficients were always  $>0.95$ . Similarly, the PCR efficiencies, assessed by the slope of the calibration curve, were optimal for all ABC transporter assays (data not shown). As shown in Fig. 1B, the slopes for *ABCG2* and *GAPDH* were very close to each other and near to the ideal value of  $-3.3$ , reflecting similar and optimum PCR efficiencies.

#### EXPRESSION ANALYSIS OF ABCG2 IN 20 DIFFERENT HUMAN TISSUES

Real-time amplification profiles for *ABCG2* in 20 human tissues are depicted as a representative example in Fig.




Fig. 2. Calibration curves constructed by measuring serial dilutions of HepG2 cDNA for the relative quantification of ABC transporter expression.

(A), amplification plots for *ABCG2* and *GAPDH* are shown, depicting normalized fluorescence values ( $\Delta R_n$ ) plotted against the number of amplification cycles. The curves represent triplicate measurements of each sample dilution. (B), the Ct values obtained from the amplification plots were used to construct calibration curves for *ABCG2* and *GAPDH*. The Ct values (*y* axis) and log of sample concentrations (*x* axis) show a reverse linear correlation with nearly identical slopes and optimum correlation coefficients.

3A. Positive reactions, and thus expression, could be achieved for all tested tissues, with heart having the lowest and uterus the highest expression of *ABCG2*. To minimize interindividual variation in the expression of ABC transporters in the different tissues, pools from tissue samples from different donors were used. On the basis of earlier reports of mRNA expression analysis in human tissue samples and because of our own experiences with real-time RT-PCR, *GAPDH* was chosen as a reference gene (15, 16). After we calculated the initial input amount from the determined Ct values, using the calibration curve method, we normalized the results to the endogenous control, *GAPDH*. The values shown in Fig. 3B represent the relative expression of *ABCG2* compared with its expression in a tissue calibrator. The expression of the calibrator, which was the tissue with the




Fig. 3. Validation of the established RT-PCR assays for quantitative detection of *ABCG2* mRNA in 20 different human tissues.

(A), real-time amplification plot for *ABCG2* in various human tissues. cDNA equivalent to 50 ng of total RNA was used for each TaqMan PCR assay. (B), Ct values obtained with different tissues were used to calculate the input amount of template by the calibration curve method. After normalization to the endogenous control, *GAPDH* (data not shown), these values were expressed relative to the calibrator (tissue with lowest expression) and displayed as relative expression (fold change; indicated by the number of ● above each column).

lowest expression, was set as 1, and the remaining samples are diagrammed as fold changes. For a better presentation, these relative expression values were translated to a linear scale (0–5) and are shown as filled circles above the columns.

We selected *ABCG2* as an example because its expression is relatively ubiquitous. Although the protein has been implicated in multidrug resistance and early hematopoiesis (8), its physiologic function has not been determined. The results of our *ABCG2* mRNA expression analysis (Fig. 3B and Table 2) agreed with the results obtained in earlier studies of *ABCG2* mRNA as well as protein analysis in human tissues (17, 18). The difference between triplicate TaqMan assays was generally <10% of

the mean value [Fig. 3B and Data Supplement (available with the online version of this article at <http://www.clinchem.org/content/vol49/issue2/>)]. *ABCG2* mRNA is highly expressed in male and female reproductive organs (uterus, prostate, and placenta) and in the small intestine, whereas the colon, heart, and skeletal muscle only marginally express this transporter mRNA. The presence of *ABCG2* in these different examined tissues reveals that this molecule is involved in the protection and/or tropic function of the reproductive system and may regulate the extrusion of substrates from intestinal cells, e.g., chemicals or, because of its homology with other members of the ABCG family, lipids (12, 19).

#### COMPLETE EXPRESSION PANEL OF ALL HUMAN ABC TRANSPORTERS IN 20 DIFFERENT TISSUES

To provide a full overview of the expression profiles of all ABC transporter mRNAs, real-time RT-PCRs were performed, and data analysis was carried out as described above and in the *Material and Methods*. Because the expression analysis of 47 different target genes in 20 human tissues yields an immense amount of data, we sought a means to display these data in a preferably concise form. Therefore, single bar graphs with the relative expression values for all of the remaining transporters are given in the Data Supplement, and the final values were translated to a linear scale and are represented as filled circles in Table 2. This type of presentation allows assessment of the expression of individual ABC transporters in all examined tissues (horizontal analysis). To compare the mRNA expression of different ABC transporters in a given tissue (vertical analysis), we have developed a color code for high (red), medium (yellow), low (blue), and very low (white) expression of transporters, based on  $\Delta Ct$  values ( $Ct_{transporter} - Ct_{GAPDH}$ ).

Analysis of all ABC transporters (Table 2) revealed that most of the genes display ubiquitous mRNA expression. However, some particular members are expressed in a very restrictive manner. This is especially true for *ABCA2* in the brain, for *ABCA3* in the lung, *ABCB4* in the liver, *ABCB11* in the liver and the testis, and *ABCG5* and *ABCG8* in the liver and the small intestine. The tissues with high expression of the seven ABC transporter subfamilies can thus be defined. It is intriguing that the tissues with highest ABC transporter expression are especially involved in secretory functions (adrenal gland) and the reproductive and tropic system (prostate, testis, uterus, and placenta) as well as barrier functions (lung, trachea, and small intestine) and metabolic activity (liver and kidney).

#### Discussion

In the present study, we have shown the successful utilization of TaqMan real-time RT-PCR for mapping of ABC transporter mRNA expression profiles in 20 different human tissues. In addition to the optimization of primers and probe sets as well as the development of 47 RT-PCR



assays, which could be particularly useful for the fields of ABC transporter research, clinical diagnosis, and drug monitoring and development, we provide comprehensive data on the expression of all human ABC transporter genes in various tissues. Because of its nature as a PCR-based method, TaqMan real-time RT-PCR is much more sensitive than conventional blot-based mRNA analysis tools, which means that the amount of starting material required (25–50 ng) is much lower than the amount needed for the most commonly used method, Northern blot analysis (5–20  $\mu$ g). The assay thus allows monitoring of mRNA expression in samples with only very limited amount of RNA as, e.g., in clinical samples such as biopsies. In addition, the high specificity of the TaqMan primer and probe sets is especially useful when analyzing a complete superfamily, as in our case all human ABC transporter genes, and allows detection of splice variants of transcripts.

In our calibration curve method, we used several dilutions of HepG2 or testis cDNA rather than purified or cloned PCR products. The advantage of our method is that with only a few cDNA samples expressing the target genes, relative quantification of many genes is possible. Therefore, the time-consuming and laborious construction of cDNA plasmids for each individual ABC transporter can be avoided. However, if cDNA plasmids were used as the calibrators, an advantage would be that they can be easily prepared in large amounts and stored for long periods in the form of bacteria cultures.

The use of housekeeping genes as internal standards needs critical consideration (20). Although the expression of *GAPDH* has been shown to vary under certain circumstances, e.g., under metabolic stimulation, in our hands, *GAPDH* was a suitable reference for expression analysis in human tissues. Certainly, alternative reference genes may be used for other cell systems.

The real-time analysis of PCR amplification also has several advantages over previous, mostly gel-based RT-PCR methods. Thus, TaqMan PCR is a closed homogeneous system without post-PCR processing and with a low contamination risk. Moreover, real-time PCR allows precise and reproducible quantification because it is based on Ct values rather than end-point detection, where the PCR components are rate limiting. Probably the most important advantage of the TaqMan chemistry and the 7900HT Sequence Detection System is the capability to rapidly monitor a large number of RNA samples in a 384-well format with minute amounts of starting material, enabling their use for high-throughput, routinely applicable assays in modern clinical laboratories. The use of additional automated equipment, such as pipetting robots and plate stackers, can further increase the number of assays to be performed.

The results obtained with our assay are consistent with those obtained in Northern blot and in situ hybridization studies with single ABC molecules (2, 18, 19, 21–33), suggesting that real-time PCR is a reliable method to quantify

ABC transporter gene expression. Moreover, the good concordance with earlier reports is particularly reflected by the expression pattern of ABC transporters with a very narrow expression profile. *ABCA2*, which has been identified as a highly expressed gene in oligodendrocytes (34, 35), was also strongly expressed in our brain samples (Fig. 2). Similarly, *ABCA3*, a lamellar body component of human lung alveolar type II cells (33, 36), was expressed exclusively in our lung samples, and the half-size transporters *ABCG5* and *ABCG8* were present only in liver and small intestine, as expected from previous reports (24, 31).

Although our study provides a complete overview of ABC transporter expression profiles in 20 human tissues and thus could be helpful for structure/function analyses of currently insufficiently characterized ABC transporters, more human tissues not present in our panel and, in particular, different cell types of organs and various human cell lines await further analysis with our assay. Moreover, protein analysis tools could be used after quantitative mRNA analysis to strengthen the expression data because it has been shown that mRNA expression does not always reflect protein concentrations.

In conclusion, the real-time RT-PCR panel for all human ABC transporters presented in this study may be a highly useful tool for (a) detecting aberrant ABC transporter gene expression in various human diseases, especially in the field of lipid disorders and multidrug resistance; (b) monitoring the pharmacologic and metabolic modulation of ABC transporter expression; and (c) performing epidemiologic studies by exploring the effects of genetic variations in ABC transporter genes.

We thank Manfred Haas and Wolfgang Hauer for excellent technical assistance. This study was funded by grants from the Deutsche Forschungsgemeinschaft (LA1203/2-1 and SFB585-02/A1) and was supported by Bayer AG and the Dietmar Hopp Foundation.

## References

1. Higgins CF. ABC transporters: from microorganisms to man. *Annu Rev Cell Biol* 1992;8:67–113.
2. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. *J Lipid Res* 2001;42:1007–17.
3. Schwiebert EM, Benos DJ, Egan ME, Stutts MJ, Guggino WB. CFTR is a conductance regulator as well as a chloride channel. *Physiol Rev* 1999;79:S145–66.
4. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. *Physiol Rev* 1999;79:S23–45.
5. Aguilar-Bryan L, Clement JP, Gonzalez G, Kunjilwar K, Babenko A, Bryan J. Toward understanding the assembly and structure of KATP channels. *Physiol Rev* 1998;78:227–45.
6. Szakacs G, Langmann T, Ozvegy C, Orso E, Schmitz G, Varadi A, et al. Characterization of the ATPase cycle of human *ABCA1*: implications for its function as a regulator rather than an active transporter. *Biochem Biophys Res Commun* 2001;288:1258–64.
7. HUGO Gene Nomenclature Committee. HGNC gene family nomen-

- clature. Human ABC-transporter genes. <http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html> (accessed, November 2002).
8. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. *Cell Mol Life Sci* 2001;58:931–59.
  9. Borst P, Zelcer N, van Helvoort A. ABC transporters in lipid transport. *Biochim Biophys Acta* 2000;1486:128–44.
  10. Lu K, Lee MH, Patel SB. Dietary cholesterol absorption; more than just bile. *Trends Endocrinol Metab* 2001;12:314–20.
  11. Schmitz G, Kaminski WE, Orso E. ABC transporters in cellular lipid trafficking. *Curr Opin Lipidol* 2000;11:493–501.
  12. Schmitz G, Langmann T, Heimerl S. Role of ABCG1 and other ABCG family members in lipid metabolism. *J Lipid Res* 2001;42:1513–20.
  13. Schmitz G, Drobnik W. ATP-binding cassette transporters in macrophages: promising drug targets for treatment of cardiovascular disease. *Curr Opin Investig Drugs* 2002;3:853–8.
  14. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of specific polymerase chain reaction product by utilizing the 5'-3' exonuclease activity of *Thermus aquaticus* DNA polymerase. *Proc Natl Acad Sci U S A* 1991;88:7276–80.
  15. Harrison DC, Medhurst AD, Bond BC, Campbell CA, Davis RP, Philpott KL. The use of quantitative RT-PCR to measure mRNA expression in a rat model of focal ischemia—caspase-3 as a case study. *Brain Res Mol Brain Res* 2000;75:143–9.
  16. Medhurst AD, Harrison DC, Read SJ, Campbell CA, Robbins MJ, Pangalos MN. The use of TaqMan RT-PCR assays for semiquantitative analysis of gene expression in CNS tissues and disease models. *J Neurosci Methods* 2000;98:9–20.
  17. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. *Cancer Res* 2001;61:3458–64.
  18. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res* 1998;58:5337–9.
  19. Klucken J, Buchler C, Orso E, Porsch OM, Liebisch G, Kapinski M, et al. ABCG1 (ABC8), the human homolog of the *Drosophila* white gene, is a regulator of macrophage cholesterol and phospholipid transport. *Proc Natl Acad Sci U S A* 2000;97:817–22.
  20. Thellin O, Zorzi W, Lakaye B, De Borman B, Coumans B, Hennen G, et al. Housekeeping genes as internal standards: use and limits. *J Biotechnol* 1999;75:291–5.
  21. Allikmets R, Gerrard B, Hutchinson A, Dean M. Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the expressed sequence tags database. *Hum Mol Genet* 1996;5:1649–55.
  22. Allikmets R, Dean M. Cloning of novel ABC transporter genes. *Methods Enzymol* 1998;292:116–30.
  23. Annilo T, Tammur J, Hutchinson A, Rzhetsky A, Dean M, Allikmets R. Human and mouse orthologs of a new ATP-binding cassette gene, ABCG4. *Cytogenet Cell Genet* 2001;94:196–201.
  24. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. *Science* 2000;290:1771–5.
  25. Engel T, Lorkowski S, Lueken A, Rust S, Schluter B, Berger G, et al. The human *abcg4* gene is regulated by oxysterols and retinoids in monocyte-derived macrophages. *Biochem Biophys Res Commun* 2001;288:483–8.
  26. Holzinger A, Kammerer S, Berger J, Roscher AA. cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. *Biochem Biophys Res Commun* 1997;239:261–4.
  27. Kaminski WE, Orso E, Diederich W, Klucken J, Drobnik W, Schmitz G. Identification of a novel human sterol-sensitive ATP-binding cassette transporter (ABCA7). *Biochem Biophys Res Commun* 2000;273:532–8.
  28. Kaminski WE, Wenzel JJ, Piehler A, Langmann T, Schmitz G. ABCA6, a novel subclass ABC transporter. *Biochem Biophys Res Commun* 2001;285:1295–301.
  29. Kaminski WE, Piehler A, Pullmann K, Porsch-Ozcuremez M, Duong C, Bared GM, et al. Complete coding sequence, promoter region, and genomic structure of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages. *Biochem Biophys Res Commun* 2001;281:249–58.
  30. Langmann T, Klucken J, Reil M, Liebisch G, Luciani MF, Chimini G, et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. *Biochem Biophys Res Commun* 1999;257:29–33.
  31. Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. *Nat Genet* 2001;27:79–83.
  32. Piehler A, Kaminski WE, Wenzel JJ, Langmann T, Schmitz G. Molecular structure of a novel cholesterol-responsive A subclass ABC transporter, ABCA9. *Biochem Biophys Res Commun* 2002;295:408–16.
  33. Yamano G, Funahashi H, Kawanami O, Zhao LX, Ban N, Uchida Y, et al. ABCA3 is a lamellar body membrane protein in human lung alveolar type II cells(1). *FEBS Lett* 2001;508:221–5.
  34. Zhao LX, Zhou CJ, Tanaka A, Nakata M, Hirabayashi T, Amachi T, et al. Cloning, characterization and tissue distribution of the rat ATP-binding cassette (ABC) transporter ABC2/ABCA2. *Biochem J* 2000;350(Pt 3):865–72.
  35. Zhou C, Zhao L, Inagaki N, Guan J, Nakajo S, Hirabayashi T, et al. Atp-binding cassette transporter ABC2/ABCA2 in the rat brain: a novel mammalian lysosome-associated membrane protein and a specific marker for oligodendrocytes but not for myelin sheaths. *J Neurosci* 2001;21:849–57.
  36. Mulugeta S, Gray JM, Notarfrancesco KL, Gonzales LW, Koval M, Feinstein SI, et al. Identification of LBM180, a lamellar body limiting membrane protein of alveolar type II cells, as the ABC transporter protein ABCA3. *J Biol Chem* 2002;277:22147–55.
  37. Taipalensuu J, Tornblom H, Lindberg G, Einarsson C, Sjoqvist F, Melhus H, et al. Correlation of gene expression of ten drug efflux proteins of the ATP-binding cassette transporter family in normal human jejunum and in human intestinal epithelial Caco-2 cell monolayers. *J Pharmacol Exp Ther* 2001;299:164–70.